

Name of the Issuer:		Vijaypd Ceutical Limited	Last updated on	07.01.2026
1	Type of Issue (IPO / FPO)		IPO	
2	Issue Size (Rs. Cr)*		19.25	
	- Fresh Issue Size (Rs. Cr)		19.25	
	- Offer for Sale Size (Rs. Cr)		-	
	*Source: Prospectus dated September 22, 2025 and Final Post issue report dated October 10, 2025			
3	Grade of issue along with name of the rating agency			
	Name	Not Applicable		
	Grade	Not Applicable		
4	Subscription Level (Number of times)		1.35*	
	Source: Final Post issue report dated October 10, 2025			
	*The above figure is after technical rejections			
5	QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges			
	Particulars %			
	(i) allotment in the issue ⁽¹⁾ 0.00%			
	(ii) at the end of 1st Quarter immediately after the listing* Not Available			
	(iii) at the end of 1st FY (March 31, 2026)* Not Available			
	(iv) at the end of 2nd FY (March 31, 2027)* Not Available			
	(v) at the end of 3rd FY (March 31, 2028)* Not Available			
	*QIB Holding not disclosed as reporting for the relevant fiscal year has not been completed.			
	(1) Source: Basis of Allotment			
6	Financials of the issuer (Standalone)			
	(In Rs. Lacs)			
	Parameters	1st FY (March 31, 2026)*	2nd FY (March 31, 2027)*	3rd FY (March 31, 2028)*
	Income from operations	Not Available	Not Available	Not Available
	Net Profit for the period	Not Available	Not Available	Not Available
	Paid-up equity share capital	Not Available	Not Available	Not Available
	Reserves excluding revaluation reserves	Not Available	Not Available	Not Available
	*Financials not disclosed as reporting for the relevant fiscal year has not been completed.			
7	Trading Status in the scrip of the issuer			
	Company's Equity Shares are listed on NSE Emerge			
	The Shares have not been suspended or delisted.			
	Particulars Status			
	(i) at the end of 1st FY (March 31, 2026)* Not Available			
	(ii) at the end of 2nd FY (March 31, 2027)* Not Available			
	(iii) at the end of 3rd FY (March 31, 2028)* Not Available			
	*Trading status not disclosed as the relevant fiscal year has not been completed.			
8	Change in Directors of issuer from the disclosures in the offer document			
	Particulars Name of the Director Appointed / Resigned			
	(i) at the end of 1st FY (March 31, 2026)* - -			
	(ii) at the end of 2nd FY (March 31, 2027)* - -			
	(iii) at the end of 3rd FY (March 31, 2028)* - -			
	Source: Stock Exchange Filings			
	* Changes in Directors of Issuer not updated as the relevant financial years have not been completed			

(i) as disclosed in the offer document	Not applicable
(ii) Actual implementation	Not applicable
(iii) Reasons for delay in implementation, if any	Not applicable

(i) as disclosed in the offer document

(Rs. Crore)

Objects of the Fresh Issue	Amount
Funding of capital expenditure requirements of our company towards the construction of Pharmaceutical API/ Intermediates and Chemicals manufacturing plant and purchase of machineries in MIDC – Shirimpur, Ahmednagar, Maharashtra	10.83
Repayment/prepayment of all or certain of our borrowings availed of by our Company;	5.1
General corporate purposes	0.74
Total	16.67

Source: Prospectus dated September 22, 2025

(ii) Actual utilization

(Rs. Crore)

Objects of the Fresh Issue	Amount
Funding of capital expenditure requirements of our company towards the construction of Pharmaceutical API/ Intermediates and Chemicals manufacturing plant and purchase of machineries in MIDC – Shirimpur, Ahmednagar, Maharashtra	Not Available
Repayment/prepayment of all or certain of our borrowings availed of by our Company;	Not Available
General corporate purposes	Not Available
Total	Not Available

(iii) Reasons for deviation, if any

Not applicable

(a) Comments on use of funds	Not Applicable, since Issue size is less than Rs. 100 crores
(b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document	
(c) Any other reservations expressed by the monitoring agency about the end use of funds	

Issue Price (Rs.):	35
Designated Stock Exchange:	NSE
Listing Date:	07-Oct-25

Price parameters	At close of listing day (October 07, 2025)	At close of 30th calendar day from listing day (November 05, 2025) ⁽¹⁾	At close of 90th calendar day from listing day (January 04, 2026) ⁽²⁾	As at the end of 1st FY after the listing of the issue (March 31, 2026)		
				Closing price	High	Low
					(during the FY)	(during the FY)
Market Price on NSE	35.90	44.00	42.30	Not Available	Not Available	Not Available
Nifty 50 *	25,108.30	25,597.65	26,328.55	Not Available	Not Available	Not Available

	As at the end of 2nd FY after the listing of the issue (March 31, 2026) ⁽³⁾⁽⁴⁾	As at the end of 3rd FY after the listing of the issue (March 31, 2027) ⁽³⁾⁽⁴⁾
Price parameters		

	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price on NSE	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available
Nifty 50 *	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available

*Being index of NSE, the designated stock exchange

Note:

(1) 30th calendar day shall be taken as listing date plus 29 calendar days.

(2) 90th calendar day shall be taken as listing date plus 89 calendar days.

(3) High and Low based on intra day prices

(4) Pricing data not disclosed as the relevant fiscal year has not completed

(5) In case of any reporting day falling on a holiday, previous trading day prices has been disclosed.

13 Basis for Issue Price-

Accounting ratio	As disclosed in the offer document ⁽¹⁾	At the end of 1st FY (March 31, 2026)	At the end of 2nd FY (March 31, 2027) ⁽²⁾	At the end of 3rd FY (March 31, 2028) ⁽²⁾
	Issuer:	3.84	Not Available	Not Available
	Peer Group:			
EPS	MedPlus Health Services Limited	3.37	Not Available	Not Available
	Entero Healthcare Solutions Limited	4.41	Not Available	Not Available
	Issuer:	9.11	Not Available	Not Available
	Peer Group:			
Price to Earnings Ratio (P/E)	MedPlus Health Services Limited	249.42	Not Available	Not Available
	Entero Healthcare Solutions Limited	256.17	Not Available	Not Available
	Issuer:	25.78	Not Available	Not Available
	Peer Group:			
NAV	MedPlus Health Services Limited	103.63	Not Available	Not Available
	Entero Healthcare Solutions Limited	379.33	Not Available	Not Available
	Issuer:	14.91%	Not Available	Not Available
	Peer Group:			
RoNW(%)	MedPlus Health Services Limited	3.32%	Not Available	Not Available
	Entero Healthcare Solutions Limited	1.17%	Not Available	Not Available

Notes:

(1) Sourced from Prospectus dated September 22, 2025

(2) Information not provided as the relevant fiscal year has not completed

Key ratios for the Company for the three fiscal years stated above are/shall be calculated as follows:

(i) Earnings per Equity Share are computed in accordance with Accounting Standard 20 "earnings per Share" notified by the Companies (Accounting Standards) Rules, 2006.

(ii) NAV per share - Net asset value per Equity Share represents net worth as at the end of the Fiscal divided by the number of Equity Shares outstanding at the end of the Fiscal

(iii) P/E - Closing Market Price as of relevant fiscal year end / Basic EPS for the Fiscal

(iv) RoNW - Return on net worth (%) is net profit attributable to equity shareholders divided by net worth for the Fiscal

14 Any other material information

Date of disclosure to Designated Stock Exchange	Announcement
Not Applicable	Not Applicable

Disclaimer:

The information compiled herein is in accordance with the disclosure requirements with regard to the track record of the public issues managed by Smart Horizon Capital Advisors Private Limited ("Smart") arising out of the SEBI Circular No. CIR/MIRSD/1/2012 dated January 10, 2012. This information is gathered from the Prospectus of the Issuer, as amended, and from the filings made by the Issuer with the BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE" and together with the BSE, the "Stock Exchanges"), as applicable, from time to time, price-volume data available on the website of the Stock Exchanges, other sources as disclosed herein and information / clarifications provided by the Issuer.

While reasonable care has been taken to ensure that the information provided herein is accurate and is taken from the sources that we believe are reliable, the user of this information may independently verify the accuracy of the information before taking any decision based on the above information.